CClinicalTrials.gg
CompletedNCT06389890PaSuTUpdated Apr 29, 2024

Pancreatic Surgery - Optimal Caseload Thresholds and Predictive Accuracy

An observational study in Volume-Outcome Relationship in Pancreatic Surgery, sponsored by Richard Hunger. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-29.

Sponsored by Richard Hunger · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
80,000
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of the study is to identify the optimal annual number of cases in a hospital with regard to minimising hospital mortality in pancreatic surgery. In particular, the prognostic value of such case numbers will be analysed.

Read the detailed description

Main research questions:

  • Can specific intervention case numbers be identified that are suitable as thresholds for annual minimum volumes and are associated with significantly low hospital mortality?
  • Almost all previous studies on case number effects have only shown a descriptive association between the number of cases in a given year and the quality of outcomes in the same year. The aim of this study is to investigate whether the correlations described can be demonstrated when using the previous year's procedure volume as a predictor. The study seeks to answer whether the procedure caseload has predictive value, specifically the number of cases in one year and in-hospital mortality in the following year.

Background:

Numerous studies have demonstrated a correlation between the number of cases and the quality of outcomes for various surgical procedures. For instance, patients who underwent surgery in high-volume hospitals (HVH) had lower mortality rates, longer survival rates, lower complication rates, and lower reoperation rates than patients who underwent surgery in low-volume hospitals (LVH). To subdivide into HVHs and LVHs, either concrete case numbers or quartile or quintile limits with an equal number of operations or clinics per group wer used. The aim of the study is to objectively determine these limits using a spline-modeled caseload term, avoiding arbitrary decisions.

One limitation of the previous findings is that they may not be generalisable due to the use of a limited number of cases and outcome quality from the same year. However, it is important to note that the volume from the previous year is crucial in determining the predictive importance of caseload for future outcome quality. A recent study (in press) reported, that there are significant fluctuations in the quality of outcomes among HVHs, even between different years. Therefore, it was hypothesized that using the number of cases as a predictor of high-quality outcomes may lead to overestimation.

Methods:

The nationwide hospital billing data for Germany (DRG statistics) for the period 2010 to 2019 will be analysed. The risk-adjusted mortality rates are determined. For this purpose, logistic regression models are calculated that adjust the mortality risk for the following variables Sex, age, emergency of admission, year of resection, diagnosis (malign neoplasm vs. benign neoplasm vs. neoplasm of unclear dignity vs. acute pancreatitis vs. chronic pancreatitis vs. other pancreatic diseases), additional procedures (venous resections/ multivisceral resections/ arterial resections/ splenectomy/ cholecystectomy/ biliary drainage/ dialysis procedures) and selected comorbidities. To classify additional procedures in order to reflect extent of surgery and technical difficulty, a slight modification of the classification system as described in Mihaljevic et al, 2021 will be used (PMID: 33386130). The Elixhauser definitions are used for the comorbidities as described in Quan et al, 2005 (PMID: 16224307). The selection of comorbidities to be considered is based on the publication by Hunger et al, 2022 (PMID: 35525416).

The case number effect is modelled using natural cubic splines. The 10th, 20th, 40th, 60th, 80th and 90th case number percentiles are used as node points. The adjusted hospital mortality as a function of the number of cases is determined using Estimated Marginal Means. Local extremes (maxima and minima) in the splines are determined using 1st and 2nd graph derivate.

Various regression models are calculated using either the number of cases from the current year of operation or the previous year. The predictive accuracy of the models is determined using the established measures from signal detection theory (AUC, sensitivity, specificity, positive predictive value, negative predictive value). Subgroup analyses for individual resection procedures will be performed.

02

Conditions studied

  • Volume-Outcome Relationship in Pancreatic Surgery

Keywords

  • Outcome Assessment
  • General Surgery
  • Pancreatic Surgery
  • Public Health
  • Hospital Planning
  • Centralized Hospital Services
03

In context

Lead sponsor

Richard Hunger is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population encompasses all patients that underwent any pancreatic resection procedure in any German hospital (full survey of the German population).

Inclusion criteria

  • at least 18 years old
  • any pancreatic resection procedure
  • operated at any German hospital

Exclusion criteria

Exclusion Criteria:

  • any transplantation procedure
  • Inpatient admission for organ removal
  • no information on sex
  • no information on age
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
80,000 participants (actual)
Patient registry
No

Groups and cohorts

  • All patients undergoing pancreatic surgery

    All patients with at least one pancreatic surgery procedure code

    Procedure: Pancreatic resection procedure

  • Subgroup: Total pancreatectomy

    All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55250', '55251', '55252', '5525x', '5525y'

    Procedure: Pancreatic resection procedure

  • Subgroup: Pancreaticoduodenectomy

    All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55241', '55242', '55243'

    Procedure: Pancreatic resection procedure

  • Subgroup: Segmental resection

    All patients with at least one of the following pancreatic procedure code (OPS-codes): '55244'

    Procedure: Pancreatic resection procedure

  • Subgroup: Distal pancreatectomy

    All patients with at least one of the following pancreatic procedure codes (OPS-codes): '55240', '552400', '552401', '552402'

    Procedure: Pancreatic resection procedure

  • Subgroup: Other partial resections

    All patients with at least one of the following pancreatic procedure codes (OPS-codes): '5524x', '5524y'

    Procedure: Pancreatic resection procedure

Interventions

  • ProcedurePancreatic resection procedure

    Pancreatic resection procedure

06

What researchers measure

Primary outcomes

  1. In-hospital mortality

    Patient died during or after surgery

    Time frame: within 30 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Data will be analyzed by controlled remote data analysis. The data is held exclusively by the Federal Statistical Office for scientific analyses. Direct access to or data sharing of individual patient data is prohibited by German law.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06389890
Lead sponsor
Richard Hunger
Collaborators
Medizinische Hochschule Brandenburg Theodor Fontane
Responsible party
Richard Hunger (Principal Investigator, Medizinische Hochschule Brandenburg Theodor Fontane) — Sponsor-investigator
First posted
Apr 29, 2024
Start date
Jan 1, 2010
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Apr 29, 2024

Study contacts

Rene Mantke, MD
study director · Head of Surgery at University Hospital Brandenburg an der Havel

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion